Industry
Biotechnology
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Loading...
Open
1.53
Mkt cap
74M
Volume
522K
High
1.73
P/E Ratio
-1.35
52-wk high
1.79
Low
1.53
Div yield
N/A
52-wk low
0.51
Portfolio Pulse from Avi Kapoor
August 16, 2024 | 10:55 am
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 11:22 am
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 8:20 pm
Portfolio Pulse from Benzinga Newsdesk
June 25, 2024 | 11:09 am
Portfolio Pulse from Benzinga Newsdesk
June 25, 2024 | 11:09 am
Portfolio Pulse from Benzinga Newsdesk
June 03, 2024 | 11:02 am
Portfolio Pulse from Benzinga Newsdesk
April 02, 2024 | 12:13 pm
Portfolio Pulse from Benzinga Newsdesk
April 01, 2024 | 11:08 am
Portfolio Pulse from Benzinga Newsdesk
December 22, 2023 | 9:14 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.